Theravance Biopharma, Inc. 8-K

What Happened
Theravance Biopharma (TBPH) announced on June 28–29, 2026 that it entered into an Agreement and Plan of Merger with Zymeworks Inc. Under the Merger Agreement, Zymeworks’ wholly owned Merger Sub will merge into Theravance, leaving Theravance as a wholly owned subsidiary of Zymeworks. At the effective time each outstanding Theravance ordinary share (other than canceled or dissenting shares) will be converted into $17.00 in cash plus one contingent value right (CVR). The parties expect the transaction to close in the second half of 2026, subject to customary conditions including shareholder approval (a two‑thirds vote) and HSR antitrust clearance.

Key Details

• Per‑share consideration: $17.00 cash plus one CVR per share; the CVR may pay contingent amounts tied to ampreloxetine.
• CVR economics: pro rata share of 80% of net license proceeds from a CVR product license (within 10 years), a $50 million first commercial sale milestone (in specified countries), and 10% of net sales (subject to terms and country‑by‑country limitations).
• Treatment of equity awards: outstanding options, RSUs and PSUs will be canceled and converted into cash payments (where in‑the‑money) and CVRs; options with exercise price ≥ $17.00 will be canceled with no payment.
• Deal mechanics & protections: expected close in H2 2026, requires Company shareholder approval (≥2/3 vote), HSR clearance; mutual termination fees of $32,515,000 in specified circumstances; Zymeworks has a financing commitment from OMERS Life Sciences, but the merger is not conditioned on financing.

Why It Matters
For Theravance shareholders, the transaction provides a certain cash value today ($17.00 per share) plus a CVR that could deliver additional payments only if specific commercial or licensing events related to ampreloxetine occur. If approved and closed, Theravance will no longer be a public company (it will be a wholly owned subsidiary of Zymeworks), and holders of stock and many equity awards will receive cash and/or CVRs rather than ongoing public equity. The CVR payments are contingent and not guaranteed, and closing remains subject to shareholder approval, antitrust clearance and other customary closing conditions. The company will file a definitive proxy statement with more details for shareholders.